Prothena Corporation plc (PRTA)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Prothena Corporation plc chart...

About the Company

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f

CEO

Gene Kinney

Exchange

NASDAQ

Website

http://www.prothena.com/

$311M

Total Revenue

148

Employees

$1B

Market Capitalization

-15.22

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PRTA News

Prothena Plc (NASDAQ: PRTA)

6d ago, source: The Motley Fool

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical ...

Prothena Corp PLC PRTA

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript

1mon ago, source: Yahoo Finance

Prothena Corporation plc misses on earnings expectations. Reported EPS is $-1.26 EPS, expectations were $-1.23. PRTA isn't one of the 30 most popular stocks among hedge funds at the end of the ...

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

1mon ago, source: Nasdaq

It had no debt as of the same date. Prothena Corporation plc Price, Consensus and EPS Surprise Revenues in 2023 totaled $91.4 million, up from $53.9 million in 2022. The figure, however ...

Prothena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 Outlook

1mon ago, source: Yahoo Finance

Warning! GuruFocus has detected 3 Warning Signs with PRTA. On February 15, 2024, Prothena Corp PLC (NASDAQ:PRTA) released its 8-K filing, detailing the financial results for the fourth quarter and ...

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

24d ago, source: Seeking Alpha

Prothena Corporation plc (NASDAQ:PRTA) is gearing up to report an update on its ongoing phase 1 study, using PRX012 for the treatment of patients with Alzheimer's Disease [AD]. It is expected that ...

Prothena Corp PLC PRTA

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

Gene Kinney : Yeah, maybe – thank you for the question and maybe I can just take this one. I think, what we’re looking for is to really have a fulsome understanding of the exposure response ...

Prothena Corporation plc

20d ago, source: U.S. News & World Report

Not all exchange-traded funds are created equal. These five-star funds are some of the cream of the ETF crop. Investing can help you reach the $1 million mark if you start early, stay in the ...

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

We appreciate your interest in Prothena and we look very much forward to sharing further updates on our program. Have a good afternoon. Operator: Thank you for participating in today’s ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...